
CLAIMS

1. A compound of the formula:



(II),

wherein:

R_1 is −H, −CN, halo, $-CF_3$, or $-C(O)R_a$, wherein R_a is −OH, $alkoxy_{(C1-4)}$, $-NH_2$, $alkylamino_{(C1-4)}$, or $-NH-S(O)_2-alkyl_{(C1-4)}$;

R_2 is hydrogen or R_2 is absent when the atom to which it is bound forms part of a double bond; and

Y is:

−H, −OH, −SH, −CN, −F, $-CF_3$, $-NH_2$ or −NCO;

$alkyl_{(C\leq8)}$, $alkenyl_{(C\leq8)}$, $alkynyl_{(C\leq8)}$, $aryl_{(C\leq12)}$, $aralkyl_{(C\leq12)}$, $heteroaryl_{(C\leq8)}$, $heterocycloalkyl_{(C\leq12)}$, $alkoxy_{(C\leq8)}$, $aryloxy_{(C\leq12)}$, $acyloxy_{(C\leq8)}$, $alkylamino_{(C\leq8)}$, $dialkylamino_{(C\leq8)}$, $alkenylamino_{(C\leq8)}$, $arylamino_{(C\leq8)}$, $aralkylamino_{(C\leq8)}$, $alkylthio_{(C\leq8)}$, $acylthio_{(C\leq8)}$, $alkylsulfonylamino_{(C\leq8)}$, or substituted versions of any of these groups;


$-alkanediyl_{(C\leq8)}-R_b$, $-alkenediyl_{(C\leq8)}-R_b$, or a substituted version of any of these groups, wherein R_b is:

hydrogen, hydroxy, halo, or amino; or

$heteroaryl_{(C\leq8)}$, $alkoxy_{(C\leq8)}$, $alkenyloxy_{(C\leq8)}$, $aryloxy_{(C\leq8)}$, $aralkoxy_{(C\leq8)}$, $heteroaryloxy_{(C\leq8)}$, $acyloxy_{(C\leq8)}$, $alkylamino_{(C\leq8)}$, $dialkylamino_{(C\leq8)}$, $alkenylamino_{(C\leq8)}$, $arylamino_{(C\leq8)}$, $aralkylamino_{(C\leq8)}$, $heteroarylamino_{(C\leq8)}$, $alkylsulfonylamino_{(C\leq8)}$, $amido_{(C\leq8)}$, $-OC(O)NH-alkyl_{(C\leq8)}$,

$-OC(O)CH_2NHC(O)O-t$-butyl, $-OCH_2-$alkylthio$_{(C\leq 8)}$, or a substituted version of any of these groups;

$-(CH_2)_mC(O)R_c$, wherein m is 0–6 and R_c is:

hydrogen, hydroxy, halo, amino, –NHOH, or ; or

alkyl$_{(C\leq 8)}$, alkenyl$_{(C\leq 8)}$, alkynyl$_{(C\leq 8)}$, aryl$_{(C\leq 8)}$, aralkyl$_{(C\leq 8)}$, heteroaryl$_{(C\leq 8)}$, heterocycloalkyl$_{(C\leq 8)}$, alkoxy$_{(C\leq 8)}$, alkenyloxy$_{(C\leq 8)}$, aryloxy$_{(C\leq 8)}$, aralkoxy$_{(C\leq 8)}$, heteroaryloxy$_{(C\leq 8)}$, acyloxy$_{(C\leq 8)}$, alkylamino$_{(C\leq 8)}$, dialkylamino$_{(C\leq 8)}$, arylamino$_{(C\leq 8)}$, alkylsulfonylamino$_{(C\leq 8)}$, amido$_{(C\leq 8)}$, $-NH-$alkoxy$_{(C\leq 8)}$, $-NH-$heterocycloalkyl$_{(C\leq 8)}$, $-NHC(NOH)-$alkyl$_{(C\leq 8)}$, $-NH-$amido$_{(C\leq 8)}$, or a substituted version of any of these groups; or


$-NHC(O)R_e$, wherein R_e is:

hydrogen, hydroxy, amino; or

alkyl$_{(C\leq 8)}$, alkenyl$_{(C\leq 8)}$, alkynyl$_{(C\leq 8)}$, aryl$_{(C\leq 8)}$, aralkyl$_{(C\leq 8)}$, heteroaryl$_{(C\leq 8)}$, heterocycloalkyl$_{(C\leq 8)}$, alkoxy$_{(C\leq 8)}$, aryloxy$_{(C\leq 8)}$, aralkoxy$_{(C\leq 8)}$, heteroaryloxy$_{(C\leq 8)}$, acyloxy$_{(C\leq 8)}$, alkylamino$_{(C\leq 8)}$, dialkylamino$_{(C\leq 8)}$, arylamino$_{(C\leq 8)}$, or a substituted version of any of these groups;

or a pharmaceutically acceptable salt or tautomer thereof.

2. The compound of claim 1, further defined by the formula:



(III),

wherein:

R_1 is −H, −CN, halo, $-CF_3$, or $-C(O)R_a$, wherein R_a is −OH, $alkoxy_{(C1-4)}$, $-NH_2$, $alkylamino_{(C1-4)}$, or $-NH-S(O)_2-alkyl_{(C1-4)}$; and

Y is:

−H, −OH, −SH, −CN, −F, $-CF_3$, $-NH_2$ or −NCO;


$alkyl_{(C\leq8)}$, $alkenyl_{(C\leq8)}$, $alkynyl_{(C\leq8)}$, $aryl_{(C\leq12)}$, $aralkyl_{(C\leq12)}$, $heteroaryl_{(C\leq8)}$, $heterocycloalkyl_{(C\leq12)}$, $alkoxy_{(C\leq8)}$, $aryloxy_{(C\leq12)}$, $acyloxy_{(C\leq8)}$, $alkylamino_{(C\leq8)}$, $dialkylamino_{(C\leq8)}$, $alkenylamino_{(C\leq8)}$, $arylamino_{(C\leq8)}$, $aralkylamino_{(C\leq8)}$, $alkylthio_{(C\leq8)}$, $acylthio_{(C\leq8)}$, $alkylsulfonylamino_{(C\leq8)}$, or substituted versions of any of these groups;

$-alkanediyl_{(C\leq8)}-R_b$, $-alkenediyl_{(C\leq8)}-R_b$, or a substituted version of any of these groups, wherein R_b is:

hydrogen, hydroxy, halo, or amino; or

$heteroaryl_{(C\leq8)}$, $alkoxy_{(C\leq8)}$, $alkenyloxy_{(C\leq8)}$, $aryloxy_{(C\leq8)}$, $aralkoxy_{(C\leq8)}$, $heteroaryloxy_{(C\leq8)}$, $acyloxy_{(C\leq8)}$, $alkylamino_{(C\leq8)}$, $dialkylamino_{(C\leq8)}$, $alkenylamino_{(C\leq8)}$, $arylamino_{(C\leq8)}$, $aralkylamino_{(C\leq8)}$, $heteroarylamino_{(C\leq8)}$, $alkylsulfonylamino_{(C\leq8)}$, $amido_{(C\leq8)}$, $-OC(O)NH-alkyl_{(C\leq8)}$, $-OC(O)CH_2NHC(O)O-t$-butyl, $-OCH_2-alkylthio_{(C\leq8)}$, or a substituted version of any of these groups;

$-(CH_2)_mC(O)R_c$, wherein m is 0–6 and R_c is:

hydrogen, hydroxy, halo, amino, –NHOH, or ; or

$alkyl_{(C\leq 8)}$, $alkenyl_{(C\leq 8)}$, $alkynyl_{(C\leq 8)}$, $aryl_{(C\leq 8)}$, $aralkyl_{(C\leq 8)}$, $heteroaryl_{(C\leq 8)}$, $heterocycloalkyl_{(C\leq 8)}$, $alkoxy_{(C\leq 8)}$, $alkenyl\text{-}oxy_{(C\leq 8)}$, $aryloxy_{(C\leq 8)}$, $aralkoxy_{(C\leq 8)}$, $heteroaryloxy_{(C\leq 8)}$, $acyloxy_{(C\leq 8)}$, $alkylamino_{(C\leq 8)}$, $dialkylamino_{(C\leq 8)}$, $arylamino_{(C\leq 8)}$, $alkylsulfonylamino_{(C\leq 8)}$, $amido_{(C\leq 8)}$, –NH–$alkoxy_{(C\leq 8)}$, –NH–$heterocycloalkyl_{(C\leq 8)}$, –NHC(NOH)–$alkyl_{(C\leq 8)}$, –NH–$amido_{(C\leq 8)}$, or a substituted version of any of these groups; or


$-NHC(O)R_e$, wherein R_e is:

hydrogen, hydroxy, amino; or

$alkyl_{(C\leq 8)}$, $alkenyl_{(C\leq 8)}$, $alkynyl_{(C\leq 8)}$, $aryl_{(C\leq 8)}$, $aralkyl_{(C\leq 8)}$, $heteroaryl_{(C\leq 8)}$, $heterocycloalkyl_{(C\leq 8)}$, $alkoxy_{(C\leq 8)}$, $aryloxy_{(C\leq 8)}$, $aralkoxy_{(C\leq 8)}$, $heteroaryloxy_{(C\leq 8)}$, $acyloxy_{(C\leq 8)}$, $alkylamino_{(C\leq 8)}$, $dialkylamino_{(C\leq 8)}$, $arylamino_{(C\leq 8)}$, or a substituted version of any of these groups;

or a pharmaceutically acceptable salt or tautomer thereof.

3. The compound of claim 2, further defined by the formula:



(IV),

wherein:

R_1 is –H, –CN, halo, $-CF_3$, or $-C(O)R_a$, wherein R_a is –OH, $alkoxy_{(C1\text{-}4)}$, $-NH_2$, $alkylamino_{(C1\text{-}4)}$, or $-NH-S(O)_2-alkyl_{(C1\text{-}4)}$; and

Y is:

−H, −OH, −SH, −CN, −F, $-CF_3$, $-NH_2$ or −NCO;


$alkyl_{(C\leq 8)}$, $alkenyl_{(C\leq 8)}$, $alkynyl_{(C\leq 8)}$, $aryl_{(C\leq 12)}$, $aralkyl_{(C\leq 12)}$, $heteroaryl_{(C\leq 8)}$, $heterocycloalkyl_{(C\leq 12)}$, $alkoxy_{(C\leq 8)}$, $aryloxy_{(C\leq 12)}$, $acyloxy_{(C\leq 8)}$, $alkylamino_{(C\leq 8)}$, $dialkylamino_{(C\leq 8)}$, $alkenylamino_{(C\leq 8)}$, $arylamino_{(C\leq 8)}$, $aralkylamino_{(C\leq 8)}$, $alkylthio_{(C\leq 8)}$, $acylthio_{(C\leq 8)}$, $alkylsulfonylamino_{(C\leq 8)}$, or substituted versions of any of these groups;

$-alkanediyl_{(C\leq 8)}-R_b$, $-alkenediyl_{(C\leq 8)}-R_b$, or a substituted version of any of these groups, wherein R_b is:

hydrogen, hydroxy, halo, or amino; or

$heteroaryl_{(C\leq 8)}$, $alkoxy_{(C\leq 8)}$, $alkenyloxy_{(C\leq 8)}$, $aryloxy_{(C\leq 8)}$, $aralkoxy_{(C\leq 8)}$, $heteroaryloxy_{(C\leq 8)}$, $acyloxy_{(C\leq 8)}$, $alkylamino_{(C\leq 8)}$, $dialkylamino_{(C\leq 8)}$, $alkenylamino_{(C\leq 8)}$, $arylamino_{(C\leq 8)}$, $aralkylamino_{(C\leq 8)}$, $heteroarylamino_{(C\leq 8)}$, $alkylsulfonylamino_{(C\leq 8)}$, $amido_{(C\leq 8)}$, $-OC(O)NH-alkyl_{(C\leq 8)}$, $-OC(O)CH_2NHC(O)O-t$-butyl, $-OCH_2-alkylthio_{(C\leq 8)}$, or a substituted version of any of these groups;

$-(CH_2)_mC(O)R_c$, wherein m is 0–6 and R_c is:

hydrogen, hydroxy, halo, amino, −NHOH, or ; or

$alkyl_{(C\leq 8)}$, $alkenyl_{(C\leq 8)}$, $alkynyl_{(C\leq 8)}$, $aryl_{(C\leq 8)}$, $aralkyl_{(C\leq 8)}$, $heteroaryl_{(C\leq 8)}$, $heterocycloalkyl_{(C\leq 8)}$, $alkoxy_{(C\leq 8)}$, $alkenyloxy_{(C\leq 8)}$, $aryloxy_{(C\leq 8)}$, $aralkoxy_{(C\leq 8)}$, $heteroaryloxy_{(C\leq 8)}$, $acyloxy_{(C\leq 8)}$, $alkylamino_{(C\leq 8)}$, $dialkylamino_{(C\leq 8)}$, $arylamino_{(C\leq 8)}$, $alkylsulfonylamino_{(C\leq 8)}$, $amido_{(C\leq 8)}$, $-NH-alkoxy_{(C\leq 8)}$, $-NH-heterocycloalkyl_{(C\leq 8)}$, $-NHC(NOH)-alkyl_{(C\leq 8)}$, $-NH-amido_{(C\leq 8)}$, or a substituted version of any of these groups; or

$-NHC(O)R_e$, wherein R_e is:

hydrogen, hydroxy, amino; or

$alkyl_{(C\leq 8)}$, $alkenyl_{(C\leq 8)}$, $alkynyl_{(C\leq 8)}$, $aryl_{(C\leq 8)}$, $aralkyl_{(C\leq 8)}$, $heteroaryl_{(C\leq 8)}$, $heterocycloalkyl_{(C\leq 8)}$, $alkoxy_{(C\leq 8)}$, $aryloxy_{(C\leq 8)}$, $aralkoxy_{(C\leq 8)}$, $heteroaryloxy_{(C\leq 8)}$, $acyloxy_{(C\leq 8)}$, $alkylamino_{(C\leq 8)}$, $dialkylamino_{(C\leq 8)}$, $arylamino_{(C\leq 8)}$, or a substituted version of any of these groups;

or a pharmaceutically acceptable salt or tautomer thereof.

4. The compound of claim 1, wherein the bond between carbon atoms 4 and 5 is a single bond.

5. The compound of claim 1, wherein the bond between carbon atoms 4 and 5 is a double bond.

6. The compound according to any one of claims 1-2 and 4-5, wherein the bond between carbon atoms 9 and 11 is a double bond.

7. The compound according to any one of claims 1-2 and 4-5, wherein the bond between carbon atoms 9 and 11 is a single bond.

8. The compound according to any one of claims 1-7, wherein R_1 is $-CN$.

9. The compound according to any one of claims 1-7, wherein R_1 is $-C(O)R_a$, wherein R_a is $-OH$, $alkoxy_{(C1-4)}$, $-NH_2$, $alkylamino_{(C1-4)}$, or $-NH-S(O)_2-alkyl_{(C1-4)}$.

10. The compound of claim 9, wherein R_a is $-OH$.

11. The compound of claim 9, wherein R_a is $alkoxy_{(C1-4)}$.

12. The compound of claim 11, wherein R_a is methoxy.

13. The compound of claim 11, wherein R_a is $-NH_2$.


14. The compound according to any one of claims 1-7, wherein R_1 is $-H$.

15. The compound according to any one of claims 1-7, wherein R_1 is halo.

16. The compound of claim 15, wherein R_1 is iodo.

17. The compound according to one of claims 1 and 6-16, wherein R_2 is hydrogen.

18. The compound according to one of claims 1 and 6-16, wherein R_2 is absent.

19. The compound according to any one of claims 1-18, wherein Y is $-(CH_2)_mC(O)R_c$, wherein m is 0–6 and R_c is hydrogen, hydroxy, amino, $-NHOH$, , $alkyl_{(C\leq8)}$, $alkenyl_{(C\leq8)}$, $alkynyl_{(C\leq8)}$, $aryl_{(C\leq8)}$, $aralkyl_{(C\leq8)}$, $heteroaryl_{(C\leq8)}$, $heterocycloalkyl_{(C\leq8)}$, $alkoxy_{(C\leq8)}$, $alkenyloxy_{(C\leq8)}$, $aryloxy_{(C\leq8)}$, $aralkoxy_{(C\leq8)}$, $acyloxy_{(C\leq8)}$, $alkylamino_{(C\leq8)}$,

dialkylamino$_{(C\leq 8)}$, arylamino$_{(C\leq 8)}$, alkylsulfonylamino$_{(C\leq 8)}$, amido$_{(C\leq 8)}$, –NH–alkoxy$_{(C\leq 8)}$, –NH–heterocycloalkyl$_{(C\leq 8)}$, –NHC(NOH)–alkyl$_{(C\leq 8)}$, –NH–amido$_{(C\leq 8)}$, or a substituted version of any of these groups other than hydrogen, hydroxy, amino, and –NHOH.

20. The compound of claim 19, wherein R_c is alkoxy$_{(C\leq 8)}$.

21. The compound of claim 20, wherein R_c is methoxy, ethoxy or isopropoxy.

22. The compound of claim 19, wherein R_c is hydroxy.

23. The compound of claim 19, wherein R_c is amino.

24. The compound of claim 19, wherein R_c is alkylamino$_{(C\leq 8)}$ or substituted alkylamino$_{(C\leq 8)}$.

25. The compound of claim 24, wherein R_c is methylamino, ethylamino, *n*-butylamino or 2,2,2-trifluoroethylamino.

26. The compound of claim 19, wherein R_c is heteroaryl$_{(C\leq 8)}$.

27. The compound of claim 26, wherein R_c is imidazolyl or dimethylimidazolyl.

28. The compound of claim 19, wherein R_c is –NHOH or –NHOCH$_3$.

29. The compound of claim 19, wherein R_c is heterocycloalkyl$_{(C\leq 8)}$ or substituted heterocycloalkyl$_{(C\leq 8)}$.

30. The compound of claim 29, wherein R_c is *N*-pyrrolidinyl, *N*-morpholinyl, *N*-piperidinyl or *N*-azetidinyl.

31. The compound of claim 19, wherein R_c is –NH–heterocycloalkyl$_{(C\leq 8)}$.

32. The compound of claim 19, wherein R_c is –NH–amido$_{(C\leq 8)}$ or a substituted version thereof.

33. The compound of claim 32, wherein, R_c is –NHNHC(O)H, –NHNHC(O)CH$_3$ or –NHNHC(O)CH$_2$OCH$_3$.

34. The compound of claim 19, wherein R_c is –NHC(NOH)CH$_3$.

35. The compound according to any one of claims 1-34, wherein m is 0.

36. The compound according to any one of claims 1-34, wherein m is 2.

37. The compound according to any one of claims 1-18, wherein Y is $-\text{alkanediyl}_{(C\leq 8)}-R_b$.

38. The compound of claim 37, wherein Y is $-CH_2-R_b$.

39. The compound according to either claim 37 or 38, wherein R_b is hydroxy.

40. The compound according to either claim 37 or 38, wherein R_b is $\text{acyloxy}_{(C\leq 8)}$ or substituted $\text{acyloxy}_{(C\leq 8)}$.

41. The compound of claim 40, wherein R_b is acetyloxy, trifluoroacetyloxy, or $-OC(O)CH_2NH_2$.

42. The compound according to either claim 37 or 38, wherein R_b is $\text{alkoxy}_{(C\leq 8)}$ or substituted $\text{alkoxy}_{(C\leq 8)}$.

43. The compound of claim 42, wherein R_b is methoxy or fluoromethoxy.

44. The compound according to either claim 37 or 38, wherein R_b is $\text{heteroaryl}_{(C\leq 8)}$.

45. The compound according to either claim 37 or 38, wherein R_b is $-OC(O)NH-\text{alkyl}_{(C\leq 8)}$, $-OC(O)CH_2NHC(O)O-t\text{-butyl}$, or $-OCH_2-\text{alkylthio}_{(C\leq 8)}$.

46. The compound according to any one of claims 1-18, wherein Y is $-CN$.

47. The compound according to any one of claims 1-18, wherein Y is isocyanate.

48. The compound according to any one of claims 1-18, wherein Y is fluoro.

49. The compound according to any one of claims 1-18, wherein Y is $\text{alkylsulfonylamino}_{(C\leq 8)}$ or substituted $\text{alkylsulfonylamino}_{(C\leq 8)}$.

50. The compound of claim 49, wherein Y is $-NHS(O)_2CH_3$ or $-NHS(O)_2CH_2CF_3$.

51. The compound according to any one of claims 1-18, wherein Y is $\text{heteroaryl}_{(C\leq 8)}$.

52. The compound of claim 51, wherein Y is oxadiazolyl, methyloxadiazolyl, or methoxymethyloxadiazolyl.

53. The compound according to any one of claims 1-18, wherein Y is $-NHC(O)R_e$, wherein R_e is hydrogen, hydroxy, amino, $alkyl_{(C\leq 8)}$, $aryl_{(C\leq 8)}$, $alkoxy_{(C\leq 8)}$, $acyloxy_{(C\leq 8)}$, $alkylamino_{(C\leq 8)}$, $dialkylamino_{(C\leq 8)}$, or substituted version of any of these groups other than hydrogen, hydroxy and amino.

54. The compound of claim 53, wherein R_e is hydrogen.

55. The compound of claim 53, wherein R_e is amino.

56. The compound of claim 53, wherein R_e is $alkyl_{(C\leq 8)}$ or substituted $alkyl_{(C\leq 8)}$.

57. The compound of claim 56, wherein R_e is methyl, ethyl, cyclopropyl, cyclobutyl, *n*-hexyl, 1,1-difluoroethyl, or 2,2,2-trifluoroethyl.

58. The compound of claim 53, wherein R_e is $aryl_{(C\leq 8)}$.

59. The compound of claim 58, wherein R_e is phenyl.


60. The compound of claim 53, wherein R_e is $alkoxy_{(C\leq 8)}$.


61. The compound of claim 60, wherein R_e is methoxy, ethoxy, or isopropoxy.


62. The compound of claim 53, wherein R_e is $alkylamino_{(C\leq 8)}$ or $dialkylamino_{(C\leq 8)}$.


63. The compound of claim 62, wherein R_e is methylamino, ethylamino, or dimethylamino.


64. The compound of claim 1, further defined as:















,



,














,


,


,






























,

,

,

,

,

,

,

,

,

,

,

,














,













,














,

,

,

,

,

,

,

,

,

,

,

,

,













,


,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,






















,

,

,

,

,

,

,

,

,

,

,

,

,

,





, or


or a pharmaceutically acceptable salt or tautomer thereof.













65. A pharmaceutical composition comprising:

a) the compound according to any one of claims1-17 and 19-64; and


b) an excipient.


66. A compound according to any one of claims 1-17 and 19-64 for use as a medicament.


67. A compound of the formula:



,

,

,

,

,

,

,

,

,

,

,

,

,



,


,


, or



,

or a pharmaceutically acceptable tautomer or salt of any of the above formulas.

C4-MONOMETHYL TRITERPENOID DERIVATIVES AND METHODS OF USE THEREOF

ABSTRACT OF THE INVENTION

Disclosed herein are novel C4-monomethyl triterpenoid compounds and derivatives thereof, including those of the formula:



(I),

wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds. Methods and intermediates useful for making the compounds, and methods of using the compounds, for example as antioxidant inflammation modulators, and compositions thereof are also provided.